EC Number   |
Title |
Organism |
|---|
    6.3.2.1 | Alanine mutation of the catalytic sites of pantothenate synthetase causes distinct conformational changes in the ATP binding region |
Mycobacterium tuberculosis |
| 6.3.2.1 | Alanine mutation of the catalytic sites of pantothenate synthetase causes distinct conformational changes in the ATP binding region |
Mycobacterium tuberculosis ATCC 25618 / H37Rv |
| 6.3.2.1 | Binding of pyrazole-based inhibitors to Mycobacterium tuberculosis pantothenate synthetase docking and MM-GB(PB)SA analysis |
Mycobacterium tuberculosis |
| 6.3.2.1 | Binding of pyrazole-based inhibitors to Mycobacterium tuberculosis pantothenate synthetase docking and MM-GB(PB)SA analysis |
Mycobacterium tuberculosis ATCC 25618 / H37Rv |
| 6.3.2.1 | Design of novel Mycobacterium tuberculosis pantothenate synthetase inhibitors virtual screening, synthesis and in vitro biological activities |
Mycobacterium tuberculosis |
| 6.3.2.1 | Design of novel Mycobacterium tuberculosis pantothenate synthetase inhibitors virtual screening, synthesis and in vitro biological activities |
Mycobacterium tuberculosis ATCC 25618 / H37Rv |
| 6.3.2.1 | Design, synthesis and biological evaluation of imidazo[2,1-b]thiazole and benzo[d]imidazo[2,1-b]thiazole derivatives as Mycobacterium tuberculosis pantothenate synthetase inhibitors |
Mycobacterium tuberculosis |
| 6.3.2.1 | Design, synthesis and biological evaluation of imidazo[2,1-b]thiazole and benzo[d]imidazo[2,1-b]thiazole derivatives as Mycobacterium tuberculosis pantothenate synthetase inhibitors |
Mycobacterium tuberculosis ATCC 27294 / ATCC 25618 / H37Rv |
| 6.3.2.1 | Identification and development of 2-methylimidazo[1,2-a]pyridine-3-carboxamides as Mycobacterium tuberculosis pantothenate synthetase inhibitors |
Mycobacterium tuberculosis |
| 6.3.2.1 | Identification and development of 2-methylimidazo[1,2-a]pyridine-3-carboxamides as Mycobacterium tuberculosis pantothenate synthetase inhibitors |
Mycobacterium tuberculosis ATCC 27294 / ATCC 25618 / H37Rv |
